Abstract: The present disclosure relates to methods, uses, medicaments, pharmaceutical formulations, dosage forms, and kits for inhibiting the progression of structural damage in psoriatic arthritis (PsA) patients using IL-17 antagonists, e.g., IL-17 antibodies and antigen-binding fragments thereof, e.g., secukinumab.

Abstract: The invention comprises a computer-implemented method comprising the steps of providing a medical dataset with data of a plurality of patients and pertaining to at least one disease, associating the data in the dataset with corresponding parts of the human body, to which the data pertains, displaying, on a display device, a graphical representation of the human body (1) or of a part of the human body, displaying, on the display device, a plurality of activatable buttons (2) associated with different parts of said graphical representation (1), receiving a user input activating one of the plurality of activatable buttons (2), and based on the activation, displaying, on the display device, a graphical representation of the data (4) associated with that part of the human body, to which the activatable button (2) activated by the user input pertains.

Abstract: The present disclosure relates to methods, uses, medicaments, pharmaceutical formulations, dosage forms, and kits for inhibiting the progression of structural damage in psoriatic arthritis (PsA) patients using Interleukin-17 (IL-17) antagonists, e.g., IL-17 antibodies and antigen-binding fragments thereof, e.g., secukinumab.

Abstract: The present disclosure relates to methods, uses, medicaments, pharmaceutical formulations, dosage forms, and kits for inhibiting the progression of structural damage in psoriatic arthritis (PsA) patients using IL-17 antagonists, e.g., IL-17 antibodies and antigen-binding fragments thereof, e.g., secukinumab.